"uuid:ID","name","instanceType","id","description","text","label"
"48528985-86eb-416e-88a2-5ee286035d46","OBJ1","Objective","Objective_1","Main objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).",""
"86627759-42e3-402b-81aa-91060b554c70","OBJ2","Objective","Objective_2","Safety","To document the safety profile of the xanomeline TTS.",""
"42f45ccd-c47f-4dae-92f9-d087267ffd3d","OBJ3","Objective","Objective_3","Behaviour","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.",""
"769f3bef-b998-4fdb-bc9a-2af1c499095a","OBJ4","Objective","Objective_4","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).",""
"89683f44-a554-4f71-9779-74cc829370e3","OBJ5","Objective","Objective_5","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).",""
"76ab6b6c-c7c2-4f02-bea5-87b1d707754d","OBJ6","Objective","Objective_6","","To assess the treatment response as a function of Apo E genotype.",""
